29 results on '"Macdonell, Richard"'
Search Results
2. Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)
3. Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis (2901)
4. Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis (2554)
5. Real-world Experience with Cladribine Tablets in the MSBase Registry (2942)
6. Delay from treatment start to full effect of immunotherapies for multiple sclerosis (2679)
7. MRI Patterns Distinguish Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis (4128)
8. Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis (2002)
9. Safety and Effectiveness of Dimethyl Fumarate Maintained Over 4 Years in Multiple Sclerosis Patients Treated in Routine Medical Practice (1346)
10. Increased John Cunningham Virus Seroconversion Rates Seen in a Southern Hemisphere International Cohort of Natalizumab Treated Patients (2291)
11. Real-world Efficacy of Delayed-Release Dimethyl Fumarate in Early Multiple Sclerosis: Interim Results from ESTEEM (P3.2-081)
12. A Prospective Study of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Identifying Ultrasonographic Features for Diagnosis and Prognosis (P2.4-001)
13. Treatment With Additional Courses of Alemtuzumab Improves Clinical and MRI Outcomes in RRMS Patients With Disease Activity After Three Courses: Analysis of CARE-MS Patients Who Received ≥4 Courses (P3.2-055)
14. Brain Volume Loss and Cognition in Teriflunomide-Treated Patients in TEMSO (P5.2-058)
15. Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS II Extension (P6.363)
16. Disability Improvement Is Observed in Each Functional System in Alemtuzumab-Treated Patients With Active RRMS: Results From CARE-MS II Extension (P6.364)
17. Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed and Other Early Multiple Sclerosis Patients, and Patients Switching from Interferon or Glatiramer Acetate, in Routine Medical Practice: Interim Results from ESTEEM (P1.367)
18. Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS I Extension (P6.362)
19. Impact of Long-term Teriflunomide Treatment on Severe Relapses: Analysis of TEMSO and TOWER Extensions (P6.361)
20. Number Needed to Treat Analyses to Assess Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Alemtuzumab or Ocrelizumab (P6.384)
21. Safety and Efficacy of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice: Interim Analysis of ESTEEM (P6.333)
22. Switching from natalizumab to fingolimod
23. Teriflunomide Shows Consistent Clinical Efficacy on Severe Relapses across Two Phase 3 Trials in Patients with Relapsing forms of Multiple Sclerosis, TEMSO and TOWER (P7.212)
24. Global Perspectives.
25. Magnetic cortical stimulation in acute spinal cord injury.
26. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
27. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
28. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
29. Evolution, current status, and way forward for the Asian Oceanian Association of Neurology.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.